Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Oncology  |  Genetic Disease

Search Medical Condition
Please enter condition
Please choose location

Neurofibromatosis Clinical Trials

A listing of Neurofibromatosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (11) clinical trials

This registry will collect information to help doctors and researchers better understand the range of medical and social problems experienced by children and adults with NF1. Volunteers will complete a 30 minute questionnaire and will be asked to update their information yearly. There are no direct benefits to the volunteers. ...

Phase

Natural History Study of Patients With Neurofibromatosis Type I

BACKGROUND: Neurofibromatosis Type 1 (NF1) is an autosomal dominant, progressive genetic disorder characterized by diverse clinical manifestations. Patients with NF1 have an increased risk of developing tumors of the central and peripheral nervous system including plexiform neurofibromas (PN), dermal neurofibromas, optic pathway tumors, brain tumors, malignant peripheral nerve sheath tumors ...

Phase N/A

Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia

The three specific aims of this study are: - Specific Aim 1 - To assess health status and health - related quality of life (HRQL) in 50 children and adolescents with NF1 and tibial dysplasia and in NF1 controls. We hypothesize that children and adolescents with NF1 and tibial dysplasia ...

Phase N/A

Collecting and Storing Information From Patients With Cancer or Other Chronic Disease Who Have Undergone Neurobehavioral Assessments on Another Clinical Trial

OBJECTIVES: Primary - Determine the neurobehavioral function of patients with chronic illness by analyzing stored data collected from IRB-approved protocols comprising retrospective data collected on protocols that are now closed and prospective data from current and future protocols. Secondary - Determine the relationship between neurobehavioral functioning and medical, neuroimaging, neurologic, ...

Phase N/A

Sunitinib in Treating Patients With Recurrent or Unresectable Meningioma Intracranial Hemangiopericytoma or Intracranial Hemangioblastoma

OBJECTIVES: Primary - To evaluate the activity of sunitinib malate in patients with recurrent meningioma as measured by 6-month progression-free survival. Secondary - To describe the response rate, median time-to-progression, and overall survival in these patient. - To evaluate the safety of sunitinib malate in patients with recurrent meningioma. Exploratory ...

Phase

Pegintron to Treat Plexiform Neurofibromas in Children and Young Adults

Background: Neurofibromatosis 1 (NF1) is a common autosomal dominant neurogenetic disorder characterized by diverse cutaneous, neurological, skeletal and neoplastic manifestations. Approximately 25 percent of individuals with NF1 develop plexiform neurofibromas (PN), which are benign nerve sheath tumors that are among the most debilitating complications of NF1. Plexiform neurofibromas may be ...

Phase

A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)

A randomized study will be performed by a multi-center group of the NF Consortium. A total of 54 patients will be randomized for treatment with or without INFUSE Bone Graft at the time of surgical repair. For all patients, a standard surgical procedure will be used, including: resection of pseudarthrosis ...

Phase

Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Neurofibromatosis type 2 (NF2) is a hereditary tumor predisposition syndrome caused by mutations in the NF2 tumor suppressor gene. Individuals with NF2 have a higher likelihood to develop multiple nervous system tumors, including schwannomas, meningiomas, and ependymomas. The hallmark of NF2 is bilateral vestibular schwannomas. Historically, most NF2 patients experience ...

Phase

Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors

This is a Phase 2 trial to assess the hearing response rate and radiographic response of VS in children and young adults with NF2 who are treated with selumetinib. Dosing will be based on age: For patients with NF2 who are 3 to < 18 years of age, dosing will ...

Phase